Vorinostat

Vorinostat (Zolinza) is an oral medication prescribed for the treatment of cutaneous (skin-related) manifestations of cutaneous T-cell lymphoma (CTCL). It works by blocking the activity of an enzyme called histone deacetylase, which may help slow or stop the growth of cancer cells. It is usually used in combination with other medications. Common side effects of Vorinostat may include nausea, diarrhea, headache, and muscle or joint pain.

Vorinostat, also known by the brand name Zolinza, is a medication used to treat a specific type of cancer called cutaneous T-cell lymphoma (CTCL) [1, 2]. Here's a breakdown of its key aspects:

Condition:

• Vorinostat is primarily used for CTCL, a rare cancer that affects T-cells (a type of white blood cell) in the skin [1].

Mechanism of Action:

• It belongs to a class of drugs called histone deacetylase (HDAC) inhibitors [2]. Normally, histone deacetylases (HDACs) are enzymes that regulate gene expression by modifying the structure of DNA packaging.
• Vorinostat works by inhibiting these enzymes, leading to changes in gene expression that can slow or stop the growth of cancer cells [2, 3].

Use:

• Vorinostat is typically used when other treatments for CTCL haven't been successful [1]. It comes in capsule form and is taken orally with food [4].

Important Considerations:

• Vorinostat can cause side effects such as fatigue, nausea, diarrhea, vomiting, hair loss, and low blood cell counts [1, 4].
• Due to the potential impact on blood cells, regular blood monitoring is necessary while taking vorinostat [4].
• Vorinostat can interact with other medications, so it's crucial to inform your doctor about all medications you're taking [4].
• It's not recommended for pregnant or breastfeeding women due to potential risks to the developing baby [4].

Additional Points:

• Research is ongoing to explore the use of vorinostat for other types of cancers beyond CTCL [5].